Pharmaceuticals & Biotech Swiss Community

1. Catalysts Evenamide (Schizophrenia Add-On Therapy): The key growth catalyst for Newron is Evenamide, a novel glutamate-modulating drug in Phase III development for treatment-resistant schizophrenia (TRS).

Valuation ### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der Ergebnisse Roche hat für das Jahr 2024 ein solides Wachstum von 7 % auf 60,5 Mrd. CHF erzielt, was die Erwartungen leicht übertroffen hat.

Catalysts Preliminary Unaudited Revenue and Cash Revenue: €266.8 million, representing a year-on-year increase of 188% compared to €92.8 million in 2023. This includes significant project-based revenues from GI Genius™ and Winlevi® of €190.2 million.

211011 Draupnir noch ein Anteil von rund 55,5% an Polypeptide. Der «Free Float» an der Börse SIX erhöht sich dadurch gleichzeitig von 40,0 auf rund 44,5%.

Key Takeaways Evolving MedTech platforms and strategic global partnerships are unlocking new markets, driving recurring revenue growth and expanding Cosmo's presence beyond its current therapy areas. Accelerated innovation, AI integration, and a strong clinical pipeline position Cosmo for high-margin, sustained earnings growth and increased resilience to market shifts.

Key Takeaways Structural cost and manufacturing advantages, combined with strong recurring revenues, position Tecan for expanding margins and resilience against macro and regulatory shocks. Accelerated innovation, increasing commercial adoption, and strategic partnerships drive faster market share gains, enabling robust, sustainable revenue and profit growth.

Key Takeaways Rising protectionism, client concentration, and generic drug adoption could curb revenue growth and pressure the company's ability to expand margins over time. Environmental regulations and talent shortages may drive up costs, erode net margins, and create operational hurdles for sustained profitability.

Key Takeaways Intensifying regulations, pricing pressures, and rising competition threaten Bachem's revenue growth, profitability, and ability to maintain premium market positioning. Large capital investments amid uncertain demand risk underutilization, weaker returns, and cash flow constraints if sector innovation or market share trends shift unfavorably.

Key Takeaways Digital transformation, AI-driven efficiencies, and ambitious M&A moves are enabling Siegfried to rapidly close margin gaps and scale global market share. Expansion into gene therapies and ESG leadership position Siegfried for outsized growth in high-demand pharma segments and premium contract wins.